EUVIMEDEUVIMED entdecken
Open Access

ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis

Darko Barisic, Christopher R Chin, Cem Meydan, Matt Teater, Ioanna Tsialta, Coraline Mlynarczyk, Amy Chadburn, Xuehai Wang, Margot Sarkozy, Min Xia, Sandra E Carson, Santo Raggiri und 12 weitere

Cancer Cell · 2024-04 · 42 (4) · 583-604.e11

DOI: 10.1016/j.ccell.2024.02.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-04. Verfasst von Darko Barisic und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA. Hauptthemen laut MEDLINE: Lymphoma, Memory B Cells. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIMH NIH HHS, Leukemia & Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ARID1A, a subunit of the canonical BAF nucleosome remodeling complex, is commonly mutated in lymphomas. We show that ARID1A orchestrates B cell fate during the germinal center (GC) response, facilitating cooperative and sequential binding of PU.1 and NF-kB at crucial genes for cytokine and CD40 signaling. The absence of ARID1A tilts GC cell fate toward immature IgM+CD80-PD-L2- memory B cells, known for their potential to re-enter new GCs. When combined with BCL2 oncogene, ARID1A haploinsufficiency hastens the progression of aggressive follicular lymphomas (FLs) in mice. Patients with FL with ARID1A-inactivating mutations preferentially display an immature memory B cell-like state with increased transformation risk to aggressive disease. These observations offer mechanistic understanding into the emergence of both indolent and aggressive ARID1A-mutant lymphomas through the formation of immature memory-like clonal precursors. Lastly, we demonstrate that ARID1A mutation induces synthetic lethality to SMARCA2/4 inhibition, paving the way for potential precision therapy for high-risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaMemory B CellsAnimalsHumansMiceDNA-Binding ProteinsMutationNuclear ProteinsTranscription Factors

Stichwörter der Autor:innen

BAF complexchromatinchromatin remodelingclonal precursor cellsepigeneticshumoral immunitylymphomapioneer transcription factorsplasticityprecision therapy

Substanzen

ARID1A protein, humanDNA-Binding ProteinsNuclear ProteinsTranscription FactorsArid1a protein, mouse

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
  • Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA; The HRH Pri…
  • Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA; The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, U…
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada.
  • Department of Biochemistry, Cell and Molecular Biology, Weill Cornell Medicine, New York, NY, USA.

Förderung

  • NCI NIH HHS
  • NIMH NIH HHS
  • Leukemia & Lymphoma Society
  • National Institutes of Health
  • Department of Latina/Latino Studies, College of Liberal Arts and Sciences, University of Illinois Urbana-Champaign
  • Terry Fox Research Institute
  • National Cancer Institute
  • Gastro-Intestinal Research Foundation

Zitieren

APA

Barisic, D., Chin, C. R., Meydan, C., Teater, M., Tsialta, I., Mlynarczyk, C., Chadburn, A., Wang, X., Sarkozy, M., Xia, M., Carson, S. E., Raggiri, S., Debek, S., Pelzer, B., Durmaz, C., Deng, Q., Lakra, P., Rivas, M., Steidl, C., …, & Melnick, A. (2024). ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell, 42(4), 583-604.e11. https://doi.org/10.1016/j.ccell.2024.02.010

Vancouver

Barisic D, Chin CR, Meydan C, Teater M, Tsialta I, Mlynarczyk C, et al. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell. 2024;42(4):583-604.e11. doi:10.1016/j.ccell.2024.02.010

BibTeX
@article{Barisic2024,
  author = {Barisic, Darko and Chin, Christopher R and Meydan, Cem and Teater, Matt and Tsialta, Ioanna and Mlynarczyk, Coraline and Chadburn, Amy and Wang, Xuehai and Sarkozy, Margot and Xia, Min and Carson, Sandra E and Raggiri, Santo and Debek, Sonia and Pelzer, Benedikt and Durmaz, Ceyda and Deng, Qing and Lakra, Priya and Rivas, Martin and Steidl, Christian and Scott, David W and Weng, Andrew P and Mason, Christopher E and Green, Michael R and Melnick, Ari},
  title = {ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {4},
  pages = {583--604.e11},
  doi = {10.1016/j.ccell.2024.02.010}
}
Kostenlos starten →